Despite advances in vaccination and antimicrobial therapy, community-acquired pneumonia remains a leading cause of morbidity and mortality, even in highly developed countries. Desmond Heng, Reginald ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "INBRIJA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets's offering. This ...

A dry powder inhaler formulation provides excellent protection against pneumonia-causing bacteria, scientists report. Community-acquired pneumonia, a type of lung inflammation contracted outside of a ...

The divided solid materials have a significant share in the products produced or employed in the pharmaceutical industries (such as active pharmaceutical ingredient (API), excipients, additives, and ...

Please provide your email address to receive an email when new articles are posted on . The dry powder formulation of treprostinil studied in BREEZE is in development with a reusable breath-powered ...

LOS ANGELES--(BUSINESS WIRE)--OTITOPIC™ recently announced a new additional indication for treatment of lung cancer for its aspirin inhalation product. Delivering an inhaled Dry Powder formulation of ...

LONDON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present ...

Dry Powder Inhalers (DPIs) are employed to supply a safe dose of Active Pharmaceutical Ingredient (API) to the deep lung. Image Credit: Freeman Technology An excipient transports the delicate ...

HUDSON, Wis., May 07, 2026--(BUSINESS WIRE)--Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and ...

Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the New ...

Dry powder inhalers (DPIs) have become a mainstay in the management of chronic pulmonary diseases such as chronic obstructive pulmonary disease and asthma. Their performance depends on a complex ...